Glaxosmithkline - Pharma mit Dividende
eröffnet am 15.07.10 17:19:04 von
neuester Beitrag 23.05.24 10:14:01 von
neuester Beitrag 23.05.24 10:14:01 von
Beiträge: 1.046
ID: 1.158.829
ID: 1.158.829
Aufrufe heute: 2
Gesamt: 129.291
Gesamt: 129.291
Aktive User: 0
ISIN: GB00BN7SWP63 · WKN: A3DMB5 · Symbol: GS71
20,420
EUR
-0,97 %
-0,200 EUR
Letzter Kurs 20:00:37 Tradegate
Meistbewertete Beiträge
| Datum | Beiträge | Bewertungen |
|---|---|---|
| 07.05.24 | ||
| 29.04.24 | ||
| 01.05.24 | ||
| 01.05.24 | ||
| 01.05.24 |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0000 | +99.999,00 | |
| 0,9998 | +122,18 | |
| 17,570 | +77,92 | |
| 34,80 | +68,93 | |
| 0,7700 | +54,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3000 | -13,91 | |
| 1,3900 | -15,76 | |
| 0,6460 | -19,25 | |
| 16,510 | -26,78 | |
| 0,7500 | -35,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
Hammer-News!
----------------------------------------
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
GSK’s two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints.
https://finance.yahoo.com/news/gsk-studies-depemokimab-sever…
----------------------------------------
GSK Breathes New Life Into Asthma Treatment With Depemokimab
Depemokimab demonstrated a significant reduction in asthma exacerbations over 52 weeks in clinical trials.
https://seekingalpha.com/article/4695015-gsk-breathes-new-li…
----------------------------------------
GSK's Depemokimab Could Be Set to Transform Asthma Treatment
In a significant breakthrough for the treatment of eosinophilic asthma, GlaxoSmithKline's (GSK) experimental drug, Depemokimab, has achieved its primary goal in a late-stage trial by significantly reducing asthma attacks.
https://www.asktraders.com/analysis/gsks-depemokimab-could-b…
----------------------------------------
🦌
Genomics plc and GSK collaborate to harness polygenic risk scores in clinical trials
Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimization of trial design. Genomics plc is a global leader in PRS-powered technologies and approaches and has developed extensive genetic databases and algorithms to understand the genetic component of diseases.
Genetic factors play a key role in disease susceptibility, progression, and response to drugs. These effects are often a result of many thousands of genetic changes that can be captured as a single number or PRS. This work will explore the opportunity for PRS-based approaches to support patient selection, and understand how that may impact clinical trials through reducing the number of patients recruited or shortening the duration of trials.
Quelle: https://www.news-medical.net/news/20240506/Genomics-plc-and-…
Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimization of trial design. Genomics plc is a global leader in PRS-powered technologies and approaches and has developed extensive genetic databases and algorithms to understand the genetic component of diseases.
Genetic factors play a key role in disease susceptibility, progression, and response to drugs. These effects are often a result of many thousands of genetic changes that can be captured as a single number or PRS. This work will explore the opportunity for PRS-based approaches to support patient selection, and understand how that may impact clinical trials through reducing the number of patients recruited or shortening the duration of trials.
Quelle: https://www.news-medical.net/news/20240506/Genomics-plc-and-…
Bye Bye 20 Euro 😍😁😁😁
Aber der eigentliche Hammer ist das hier:
"Wir haben einen starken Start in das Jahr 2024 hingelegt, mit einem weiteren Quartal hervorragender Leistungen und anhaltenden Fortschritten in unserer Pipeline, einschließlich positiver Daten für vier Phase-III-Medikamente", sagte Unternehmenschefin Emma Walmsley laut einer Mitteilung am Mittwoch.
GSK erhöht Gewinnziel für 2024
Der Pharmakonzern GSK ist besser als erwartet in das neue Jahr gestartet.
Für das Gesamtjahr hob das Unternehmen seine Gewinnziele an.
Quelle: https://de.marketscreener.com/kurs/aktie/GSK-PLC-9590199/new…
🎁
Trading Spotlight
In London ist die Börse heute geöffnet:
🦌
🦌
Q1 2024 results announcement
Positiver Trend geht weiter:https://www.gsk.com/en-gb/media/press-releases/gsk-makes-a-s…
Hauptsache der Kurs läuft in die richtige Richtung.
nächste "Analyse" mit 2040 pence 🤔 ... die scheinen alle irgendwie andere Bewertungsmodelle zu haben 🤪🤑.
irgendwie war JPMorgan noch nie "Fan" von GSK 🤔 ... 1530 pence als KZ 🧐. irgendwie hat bei Pharma jeder seinen eigenen Ansatz 🤑 .... sind halt "Analysten" (Arbeitsnachweis erbringen 🙈😴😴😴).
Durchsuchen
13.05.24 · wallstreetONLINE Redaktion · Amazon |
01.05.24 · dpa-AFX · Advanced Micro Devices |
01.05.24 · dpa-AFX · GSK |
01.05.24 · wallstreetONLINE Redaktion · Allstate |
30.04.24 · BörsenNEWS.de · Allstate |
18.04.24 · dpa-AFX · Bayer |
20.03.24 · dpa-AFX · GSK |
19.03.24 · wallstreetONLINE Redaktion · Morphosys |
18.03.24 · wallstreetONLINE Redaktion · Pfizer |
17.03.24 · dpa-AFX · CureVac |